PMC:7546716 / 207-592 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T4","span":{"begin":41,"end":49},"obj":"Body_part"},{"id":"T5","span":{"begin":51,"end":62},"obj":"Body_part"},{"id":"T6","span":{"begin":64,"end":66},"obj":"Body_part"},{"id":"T7","span":{"begin":232,"end":234},"obj":"Body_part"},{"id":"T8","span":{"begin":275,"end":280},"obj":"Body_part"},{"id":"T9","span":{"begin":340,"end":358},"obj":"Body_part"},{"id":"T10","span":{"begin":353,"end":358},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma84070"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":" a pathogenic model in which the alarmin cytokine, interleukin (IL)-33, is a key player in driving all stages of COVID-19 disease (ie, asymptomatic, mild–moderate, severe–critical, and chronic–fibrotic). In susceptible individuals, IL-33 release by damaged lower respiratory cells might induce dysregulated GATA-binding factor 3-expressing regulatory T cells, thereby breaking immune t"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T3","span":{"begin":113,"end":121},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":" a pathogenic model in which the alarmin cytokine, interleukin (IL)-33, is a key player in driving all stages of COVID-19 disease (ie, asymptomatic, mild–moderate, severe–critical, and chronic–fibrotic). In susceptible individuals, IL-33 release by damaged lower respiratory cells might induce dysregulated GATA-binding factor 3-expressing regulatory T cells, thereby breaking immune t"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":1,"end":2},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T2","span":{"begin":75,"end":76},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":275,"end":280},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T4","span":{"begin":340,"end":358},"obj":"http://purl.obolibrary.org/obo/CL_0000815"}],"text":" a pathogenic model in which the alarmin cytokine, interleukin (IL)-33, is a key player in driving all stages of COVID-19 disease (ie, asymptomatic, mild–moderate, severe–critical, and chronic–fibrotic). In susceptible individuals, IL-33 release by damaged lower respiratory cells might induce dysregulated GATA-binding factor 3-expressing regulatory T cells, thereby breaking immune t"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":64,"end":66},"obj":"Chemical"},{"id":"T3","span":{"begin":232,"end":234},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A2","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A4","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":" a pathogenic model in which the alarmin cytokine, interleukin (IL)-33, is a key player in driving all stages of COVID-19 disease (ie, asymptomatic, mild–moderate, severe–critical, and chronic–fibrotic). In susceptible individuals, IL-33 release by damaged lower respiratory cells might induce dysregulated GATA-binding factor 3-expressing regulatory T cells, thereby breaking immune t"}

{"project":"LitCovid-PubTator","denotations":[{"id":"23","span":{"begin":51,"end":70},"obj":"Gene"},{"id":"24","span":{"begin":232,"end":237},"obj":"Gene"},{"id":"25","span":{"begin":307,"end":328},"obj":"Gene"},{"id":"37","span":{"begin":113,"end":121},"obj":"Disease"}],"attributes":[{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"Gene:90865"},{"id":"A24","pred":"tao:has_database_id","subj":"24","obj":"Gene:90865"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"Gene:2625"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" a pathogenic model in which the alarmin cytokine, interleukin (IL)-33, is a key player in driving all stages of COVID-19 disease (ie, asymptomatic, mild–moderate, severe–critical, and chronic–fibrotic). In susceptible individuals, IL-33 release by damaged lower respiratory cells might induce dysregulated GATA-binding factor 3-expressing regulatory T cells, thereby breaking immune t"}